hdr isap 2019

News September 2021

ISAP-EPASG Meeting November 12-13 2021


Dear ISAP members,

We are pleased to share the first circular of our program for the upcoming ISAP-EPASG Meeting on November 12-13 2021. The meeting will start at 1.00 PM CET on November 12 and finish at 14.15PM on November 13. Please find the current version of the program here.

Call for abstracts for the Young Investigator Session
As per ISAP tradition, also the upcoming meeting will contain a Young Investigator Session, which is organised by Alina Nussbaumer-Pröll (Vienna, Austria) and Elisabet Nielsen (Uppsala, Sweden). We encourage all Young Investigators to actively contribute by submitting abstracts for a 5–10-minute oral talk (depending on the number of participants) about your current data or project followed by 2–5-minutes questions and answers. You are also welcomed to present data that has been already approved at ECCMID 2021. To submit abstracts, we would ask you to send an e-mail with your abstract (in any format) to This email address is being protected from spambots. You need JavaScript enabled to view it. until the 10th of October. Abstracts will be reviewed by the scientific committee. Please include your affiliation and full name.

Best regards,

ISAP Council 

News April 2021

Virtual ISAP Meeting May 2021

After our first successful virtual meeting in February, we would like to invite you to our 2nd virtual ISAP meeting:

The meeting will take place in the US/European time zone on May 26 2021 4PM - 6PM CEST and will be held online.

The meeting will start with a keynote presentation by Dr. Sujata Bhavnani (NY, USA) with a presentation titled:

"Antimicrobial Therapy:  Precision Medicine and Beyond"

After the keynote, five Young Investigators from all around the globe will share their research:
Presenter Title
Sue Nang Polymyxins: 'Pseudo'-resistance in Klebsiella pneumoniae
Johanna Seeger Quantification of persister formation of Escherichia coli lerveraging electronic cell counting and semi-mechanistic pharmacokinetic/pharmacodynamic modelling
Lisa Amann Continuous infusion of tigecycline as an improved treatment option? Insights from a hollow fiber study
Karol Sokolowski  Evaluating Glutathione-conjugated Hydrogels as Localized Antibiotic Delivery Vehicles for Treatment of Bacterial Infections
David Busse Probability of target attainment of antibiotics in obese patients: Do conventional pharmacokinetic/pharmacodynamic targets adequately capture target-site penetration?" 

Dial-in information are shared via the Newsletter - check your inbox!


News January 2021

Virtual US/Australian Virtual ISAP Scientific Meeting 

As discussed in our Annual Meeting in the fall, we wanted to initiate a ‘time-zone optimized’ virtual meeting series to foster scientific exchange and give our Young Investigators the opportunity to present their research. We are happy to announce that we will start this series in the US/Australian time zone on February 2 2021 5 PM (Orlando time) / February 3 2021 9 AM (Melbourne time).
The meeting will start with a keynote presentation, delivered by two excellent speakers from our community:
Dr. Cornelia Landersdorfer (Monash University, Australia) and Dr. Jürgen Bulitta (University of Florida, USA) will deliver a presentation entitled

 ‘Novel approaches to leverage molecules assays and disease-specific pharmacokinetics for translational antimicrobial pharmacology’.

After the keynote, there will be opportunities for Young Investigators to present their research.

The following Young Investigators will present their research:



Xingchen Bian

Is withdrawal of polymyxin breakpoints by CLSI justified: A Chinese perspective on intravenous polymyxin B for the treatment of bloodstream infection caused by multidrug-resistant Gram-negative pathogens.

Akosua Adom Agyeman

Evaluation of meropenem and tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa strains via the dynamic hollow fibre infection model and mechanism-based modelling.

Nitin Patil

The Critical Role of Position 10 Residue in the Polymyxin Antimicrobial Activity

Yang Hu 

Perturbations of gut microbiome in mice by polymyxin treatments 

Yinzhi Lang  Novel cassette assays to quantify the outer membrane permeability of β-lactams in carbapenem-resistant Gram-negative bacteria
Alaa Sayed Inhibitory Binding Profiles for β-lactams and Penicillin-Binding Proteins in Mycobacterium abscessus
Jieqiang Zhou Thermal stability of β-lactam antibiotics in broth, agar and water: Precisely achieving target concentrations in vitro by supplement dosing algorithm that offset thermal degradation
Yan Zhu Unculturable Acinetobacter baumannii escapes from polymyxin killing via dependent

Dial-in information have been sent via the newsletter!


News March 2021


On Tuesday, March 9 2021 at 12.30PM CET, Dr Shampa Das, Liverpool, UK will deliver a webinar on the topic "Considerations in the use of PK-PD and probability of target attainment analysis in breakpoint setting."

The webinar is free for ISAP members and the dial-in information will be send to ISAP members via the newsletter.

News November 2020

ISAP mourns the passing of Hartmut Derendorf

Dear colleagues and friends,

On November 23, 2020, our community lost a giant in our field and a remarkable human being: With heavy heart, we would like to share with you the devastating news that Hartmut Derendorf, Ph.D., our former President and longstanding ISAP member, passed away unexpectedly at the age of 67.

After studying Pharmacy and obtaining his Ph.D. in 1979 from the University of Münster, Germany, he joined the College of Pharmacy at the University of Florida, Gainesville, USA as a postdoctoral fellow in 1981, became a faculty member in 1983, and chaired the Department of Pharmaceutics for more than 25 years until his retirement in 2018. During that time, Hartmut become a leader in the field of modern pharmacokinetics and pharmacodynamics, long before such “scientific questions became mainstream questions”, as noted by his colleague and friend Ursula Theuretzbacher. Indeed, Hartmut mentored over 70 graduate students and 40 postdoctoral fellows and published over 500 publications. He earned numerous national and international awards for his research, e.g. the Volwiler Research Achievement Award from the American Association of Colleges of Pharmacy as well as the American College of Clinical Pharmacology (ACCP), Distinguished Investigator Award. Hartmut was also a former review panel member of the NASA Human Research Program, which investigated drug use during spaceflight, indicating the wide outreach of his research.

Our colleague Paul Tulkens remembered when Hartmut joined ISAP in 1995 at one of the founding meetings in Quebec City, Canada: “Hartmut presented a poster that we all very much appreciated because of its high scientific pharmacological content.  We all saw him as one of the future leaders in the discipline of antimicrobial PK/PD”, Paul said. He was right. Since then Hartmut was a longstanding, extremely active and passionate ISAP member. He served as President of ISAP from 2004-2006 and was a Council member for countless years until only a few weeks ago. He shaped the society tremendously. Roger Nation noted that Hartmut “had a deep love for ISAP and was a passionate advocate for its role in fostering the development of emerging antimicrobial chemotherapy scientists.” As an exceptional educator and caring mentor, he touched numerous lives, and inspired many young fellows to pursue a career in PK/PD and antimicrobial pharmacology, including myself. Hartmut did not only inspire, but took his role as a mentor very seriously and was “supportive like a father” of so many of us, as noted by Markus Zeitlinger.

Our thoughts are with his wife Kerry, his family and friends during this time of grieving the loss of this remarkable human being, who was not only an extremely gifted scientist, but also a humble and kind person with a heart of gold, positive attitude and sense of humor. He will be deeply missed by all of us.
Sebastian G. Wicha, President
on behalf of the International Society of Anti-Infective Pharmacology (ISAP)